Literature DB >> 22777388

p38 Mitogen-activated protein kinase/signal transducer and activator of transcription-3 pathway signaling regulates expression of inhibitory molecules in T cells activated by HIV-1-exposed dendritic cells.

Karlhans Fru Che1, Esaki Muthu Shankar, Sundaram Muthu, Sasan Zandi, Mikael Sigvardsson, Jorma Hinkula, Davorka Messmer, Marie Larsson.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection enhances the expression of inhibitory molecules on T cells, leading to T-cell impairment. The signaling pathways underlying the regulation of inhibitory molecules and subsequent onset of T-cell impairment remain elusive. We showed that both autologous and allogeneic T cells exposed to HIV-pulsed dendritic cells (DCs) upregulated cytotoxic T-lymphocyte antigen (CTLA-4), tumor-necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), lymphocyte-activation gene-3 (LAG3), T-cell immunoglobulin mucin-3 (TIM-3), CD160 and certain suppression-associated transcription factors, such as B-lymphocyte induced maturation protein-1 (BLIMP-1), deltex homolog 1 protein (DTX1) and forkhead box P3 (FOXP3), leading to T-cell suppression. This induction was regulated by p38 mitogen-activated protein kinase/signal transducer and activator of transcription-3 (P38MAPK/STAT3) pathways, because their blockade significantly abrogated expression of all the inhibitory molecules studied and a subsequent recovery in T-cell proliferation. Neither interleukin-6 (IL-6) nor IL-10 nor growth factors known to activate STAT3 signaling events were responsible for STAT3 activation. Involvement of the P38MAPK/STAT3 pathways was evident because these proteins had a higher level of phosphorylation in the HIV-1-primed cells. Furthermore, blockade of viral CD4 binding and fusion significantly reduced the negative effects DCs imposed on primed T cells. In conclusion, HIV-1 interaction with DCs modulated their functionality, causing them to trigger the activation of the P38MAPK/STAT3 pathway in T cells, which was responsible for the upregulation of inhibitory molecules.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22777388      PMCID: PMC3510300          DOI: 10.2119/molmed.2012.00103

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  54 in total

Review 1.  PD-1 and its ligands in T-cell immunity.

Authors:  Mary E Keir; Loise M Francisco; Arlene H Sharpe
Journal:  Curr Opin Immunol       Date:  2007-04-12       Impact factor: 7.486

2.  Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  Nature       Date:  2007-01-14       Impact factor: 49.962

3.  C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cells.

Authors:  Makoto Sugaya; Oliver Hartley; Michael J Root; Andrew Blauvelt
Journal:  J Invest Dermatol       Date:  2007-01-25       Impact factor: 8.551

4.  Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.

Authors:  Heather M Gibson; Carrie J Hedgcock; Barbara M Aufiero; Adam J Wilson; Mikehl S Hafner; George C Tsokos; Henry K Wong
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

Review 5.  Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

Authors:  Hua Yu; Marcin Kortylewski; Drew Pardoll
Journal:  Nat Rev Immunol       Date:  2007-01       Impact factor: 53.106

6.  Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Authors:  Jean-René Pallandre; Emilie Brillard; Gilles Créhange; Amandine Radlovic; Jean-Paul Remy-Martin; Philippe Saas; Pierre-Simon Rohrlich; Xavier Pivot; Xiang Ling; Pierre Tiberghien; Christophe Borg
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 7.  Role of Stat3 in suppressing anti-tumor immunity.

Authors:  Marcin Kortylewski; Hua Yu
Journal:  Curr Opin Immunol       Date:  2008-05-12       Impact factor: 7.486

8.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.

Authors:  Daniel E Kaufmann; Daniel G Kavanagh; Florencia Pereyra; John J Zaunders; Elizabeth W Mackey; Toshiyuki Miura; Sarah Palmer; Mark Brockman; Almas Rathod; Alicja Piechocka-Trocha; Brett Baker; Baogong Zhu; Sylvie Le Gall; Michael T Waring; Ryan Ahern; Kristin Moss; Anthony D Kelleher; John M Coffin; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker
Journal:  Nat Immunol       Date:  2007-09-30       Impact factor: 25.606

Review 9.  Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution.

Authors:  Bharat B Aggarwal; Gautam Sethi; Kwang Seok Ahn; Santosh K Sandur; Manoj K Pandey; Ajaikumar B Kunnumakkara; Bokyung Sung; Haruyo Ichikawa
Journal:  Ann N Y Acad Sci       Date:  2006-12       Impact factor: 5.691

10.  HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells.

Authors:  Meimei Shan; Per Johan Klasse; Kaustuv Banerjee; Antu K Dey; Sai Prasad N Iyer; Robert Dionisio; Dustin Charles; Lila Campbell-Gardener; William C Olson; Rogier W Sanders; John P Moore
Journal:  PLoS Pathog       Date:  2007-11       Impact factor: 6.823

View more
  25 in total

Review 1.  Animal models for viral infection and cell exhaustion.

Authors:  Colleen S McGary; Guido Silvestri; Mirko Paiardini
Journal:  Curr Opin HIV AIDS       Date:  2014-09       Impact factor: 4.283

Review 2.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Authors:  Christine Katlama; Steven G Deeks; Brigitte Autran; Javier Martinez-Picado; Jan van Lunzen; Christine Rouzioux; Michael Miller; Stefano Vella; Joern E Schmitz; Jeffrey Ahlers; Douglas D Richman; Rafick P Sekaly
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

Review 3.  Host Methyltransferases and Demethylases: Potential New Epigenetic Targets for HIV Cure Strategies and Beyond.

Authors:  Daniela Boehm; Melanie Ott
Journal:  AIDS Res Hum Retroviruses       Date:  2017-11       Impact factor: 2.205

Review 4.  PD-1 coinhibitory signals: the link between pathogenesis and protection.

Authors:  Deanna A Kulpa; Mariam Lawani; Anthony Cooper; Yoav Peretz; Jeff Ahlers; Rafick-Pierre Sékaly
Journal:  Semin Immunol       Date:  2013-03-31       Impact factor: 11.130

5.  Blimp-1, an intrinsic factor that represses HIV-1 proviral transcription in memory CD4+ T cells.

Authors:  Katarzyna Kaczmarek Michaels; Malini Natarajan; Zelda Euler; Galit Alter; Gregory Viglianti; Andrew J Henderson
Journal:  J Immunol       Date:  2015-02-20       Impact factor: 5.422

6.  Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+ T Cells.

Authors:  Nitasha A Kumar; Renee M van der Sluis; Talia Mota; Rachel Pascoe; Vanessa A Evans; Sharon R Lewin; Paul U Cameron
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

7.  Human Th17 Cells Lack HIV-Inhibitory RNases and Are Highly Permissive to Productive HIV Infection.

Authors:  Aaron Christensen-Quick; Mark Lafferty; Lingling Sun; Luigi Marchionni; Anthony DeVico; Alfredo Garzino-Demo
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

8.  HIV-1 gp120 activates the STAT3/interleukin-6 axis in primary human monocyte-derived dendritic cells.

Authors:  Manuela Del Cornò; Gloria Donninelli; Barbara Varano; Letizia Da Sacco; Andrea Masotti; Sandra Gessani
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

Review 9.  Recent advances on T-cell exhaustion in malaria infection.

Authors:  Esaki M Shankar; R Vignesh; A P Dash
Journal:  Med Microbiol Immunol       Date:  2018-06-23       Impact factor: 3.402

Review 10.  Molecular signatures of T-cell inhibition in HIV-1 infection.

Authors:  Marie Larsson; Esaki M Shankar; Karlhans F Che; Alireza Saeidi; Rada Ellegård; Muttiah Barathan; Vijayakumar Velu; Adeeba Kamarulzaman
Journal:  Retrovirology       Date:  2013-03-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.